WO 2005/000830 PCT/GB2004/002714

- 20 ~

Claims:

1. A pharmaceutical composition (excluding smoked cannabis) comprising at least one compound of the general

5 formula 1

Formula 1

R¹ R²

where;

15 R^1 is OH;

R2 is H or COOH;

 R^3 is C_1-C_8 alkyl group; and

and R4 is H

or a derivative thereof for use in treating mood disorders.

20

10

- 2. A pharmaceutical composition as claimed in claim 1 wherein \mathbb{R}^3 is a C1-C5 alkyl group.
- A pharmaceutical composition as claimed in claim 1
 wherein R³ is a C3-C5 alkyl group.
 - 4. A pharmaceutical composition as claimed in any one of claims 1 to 3 wherein R^3 is a straight chain alkyl group.
- 30 5. A pharmaceutical composition as claimed in claim 1 wherein R^3 is C_5H_{11} .
 - 6. A pharmaceutical composition as claimed in claim 1 wherein R^3 is C_3H_7 .

35

- 7. A pharmaceutical composition as claimed in any of the preceding claims, which comprises an extract of one or more cannabis plants.
- 40 8. A pharmaceutical composition as claimed in claim 7 wherein the extract comprises substantially all the naturally

WO 2005/000830 PCT/GB2004/002714

- 21 -

occurring cannabinoids in said plant(s).

9. A pharmaceutical composition as claimed in claim 1 which comprises an extract of one or more cannabis plants, which extract is enriched for cannabichromene.

- 10. A pharmaceutical composition as claimed in any of claims 1 to 4 which comprises, as the active pharmaceutical agent, an isolated and substantially pure preparation of a compound according to formula 1.
- 11. A pharmaceutical composition as claimed in any of the preceding claims which is formulated for delivery nasally, sublingually, buccally, topically, orally, rectally, intravenously, intra-peritoneally, intra-muscularly, subcutaneously, transdermally, intra-vaginally, intra-ureathrally, by nebuliser, as inhaled vapour or by installation directly into the bladder.
- 20 12. A pharmaceutical composition as claimed in any of the preceding claims wherein said composition comprises, in addition to the pharmaceutically active ingredient, one or more pharmaceutically acceptable diluents, excipients or carriers.
- 25 13. A pharmaceutical composition as claimed in any of the preceding claims for use in the treatment of morbid or clinical depression, unipolar mood disorder, bipolar mood disorder, syndromal depression, panic disorder or anxiety.
- 14. A method of treating a mood disorder in a human patient, which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of Formula 1 as defined in claim 1 or a pharmaceutical composition according to any one of claims 1 to 13.
 - 15. Method according to claim 14 wherein the mood disorder is morbid or clinical depression, unipolar mood disorder, bipolar mood disorder, syndromal depression, panic disorder or anxiety.

35

, g > .

5

10

WO 2005/000830 PCT/GB2004/002714

- 22 -

- 16. Use of a compound of formula 1 as defined in claim 1 for the manufacture of a medicament for the treatment of a mood disorder.
- 5 17. Use according to claim 16 wherein the mood disorder is morbid or clinical depression, unipolar mood disorder, bipolar mood disorder, syndromal depression, panic disorder or anxiety.
- 18. Use according to claim 16 or claim 17 wherein the compound of formula 1 is present in an extract of at least one cannabis plant.